| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Eye Institute (NEI) |
| Information provided by: | National Eye Institute (NEI) |
| ClinicalTrials.gov Identifier: | NCT00000132 |
Purpose
The primary purpose is to compare the effect of immediate therapy to lower the intraocular pressure (IOP) versus late or no treatment on the progression of newly detected open-angle glaucoma, as measured by increasing visual field loss and/or optic disc changes.
The secondary purposes are to determine the extent of IOP reduction attained by treatment, to explore factors that may influence glaucoma progression, and to describe the natural history of newly detected glaucoma.
| Condition | Intervention | Phase |
|
Open-Angle Glaucoma |
Drug: Betaxolol Procedure: Argon Laser Trabeculoplasty |
Phase III |
| Genetics Home Reference related topics: | early-onset glaucoma |
| MedlinePlus related topics: | Glaucoma |
| Drug Information available for: | Betaxolol Betaxolol hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized |
Eligibility
| Ages Eligible for Study: | 50 Years to 80 Years |
| Genders Eligible for Study: | Both |
Men and women between ages 50 and 80 years who have newly detected and untreated chronic open-angle glaucoma with repeatable visual field defects by Humphrey perimetry are eligible for inclusion.
Exclusion criteria include the following: advanced visual field loss (MD less than or equal to 16 dB) or threat to fixation; mean IOP > 30 mm Hg or any IOP > 35 mm Hg in at least one eye; VA < 0.5 in either eye; or any conditions precluding reliable fields or photos, use of study treatment, or 4-year followup.
Contacts and Locations More Information
| Study ID Numbers: | NEI-31 |
| First Received: | September 23, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000132 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
